Bio-Rad Expands Joint Marketing Agreement with Siemens Healthineers, Providing Quality Controls to Optimize Efficiency and Data Reliability
HERCULES, Calif. – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products today announced the expansion of its joint marketing agreement with Siemens Healthineers in which Bio-Rad will provide quality control products and Unity Quality Control data management solutions for Siemens Healthineers’ Atellica® Solution platforms.
The agreement establishes Bio-Rad’s preferred supplier status with Siemens Healthineers, providing clinical laboratories within the Siemens Healthineers clinical laboratory systems portfolio with Bio-Rad quality controls and now includes InteliQ, a range of barcoded, load-and-go quality controls in a tube configuration that provide efficiencies in workflow and data management.
As part of the agreement, clinical laboratories using Bio-Rad controls and Siemens Healthineers’ proprietary-labeled controls on their immunoassay and chemistry systems may participate in Bio-Rad's comprehensive Unity Interlaboratory Program. The Unity software products offer varying levels of functionality ranging from basic Internet-based data submission to advanced real-time QC data management, rules evaluation, and analysis.
"We are pleased to extend our partnership with Siemens Healthineers to offer customers access to Bio-Rad's comprehensive line of multi-analyte quality controls and QC data management solutions," said Dara Wright, Bio-Rad Clinical Diagnostics Group EVP & President. "Our quality controls and data management solutions combined with our customer training and support services help to strengthen the performance of clinical labs to ensure the most reliable data is provided to physicians."
Bio-Rad offers an extensive range of quality controls covering analytes for immunoassay, chemistry, cardiac assessment, immunology, diabetes, coagulation, hematology, blood gas, drugs-of-abuse, and infectious disease testing. The company’s QC data management solutions connect large peer groups of test systems and assay methods to the company’s Unity Interlaboratory Program, enabling labs to compare their results in real time with over 25,000 other labs worldwide.
INTELIQ, UNITY and BIO-RAD are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make that we will provide quality control products and Unity Quality Control data management solutions for Siemens Healthineers’ Atellica® Solution platforms and regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Tina Cuccia, Manager